Vanderbilt University Medical Center

This episode focuses on the complex management of recurrent low-grade bladder tumors and highlights the limitations and challenges of current treatments, including intravesical chemotherapy and BCG, and underscores the need for better therapies and clinical trials in this area.

The various treatment approaches for NMIBC in the context of a BCG shortage, with a focus on initial cases, are shared. Urologists discuss their strategies for treating a hypothetical patient with a 3 cm bladder tumor, weighing options like perioperative chemotherapy, the importance of thorough resection, and adapting treatment protocols based on tumor characteristics and the ongoing BCG shortage.

The impact of the BCG shortage on the treatment of bladder cancer, exploring various strategies adopted by urologists to optimize patient care. The conversation highlights the importance of risk stratification in deciding treatment protocols, considering factors like tumor size, location, multifocality, and histology, as well as patient age and overall health.

Amy Luckenbaugh, MD, is an assistant professor of Urology at Vanderbilt University Medical Center.

Experts discuss grading, staging, and risk stratification of Non-Muscle Invasive Bladder Cancer (NMIBC). Panelists highlight differentiation between the risks of recurrence and progression, emphasizing the importance of categorizing patients into low, intermediate, and high-risk groups based on various factors, including tumor size, grade, and history of recurrence. The importance of continuous prospective observation of patients with NMIBC is emphasized.

Experts in urology discuss the importance of evaluation to accurately identify the stage and grade of NMIBC, which plays a crucial role in determining the risk category focusing on the distinction between low and high-grade tumors and the significance for each patient with NMIBC​​.

“When it comes to this, I think having a great team around you is really so important,” says Bree Duncan, RN, BSN.

“I think being younger and going through something so scary, I think it's been really important to her to have someone with her throughout the whole process,” says Bree Duncan, RN, BSN.

“We found that these genetic proxies of thiazide diuretics were associated with a 15% lower risk of kidney stones,” says Jefferson Triozzi, MD.

"There are a lot of questions and issues regarding [topics] like body image and sexual function, and things like that, that also, being a woman in this role, I feel like they feel comfortable asking me those questions," says Bree Duncan, RN, BSN.

"My goal is to always meet them there in clinic, and then just start that relationship, in a sense of, I'm there for whatever they need," says Bree Duncan, RN, BSN.

The phase 2a open-label dose ascending study to assess the safety, tolerability, and efficacy of VMB-100 in female patients with moderate SUI is expected to begin in the first half of 2024.

"We as a specialty have to do a better job of educating our colleagues and referring docs," says Roger R. Dmochowski, MD, MMHC, FACS

W. Kimryn Rathmell, MD, PhD, an internationally recognized expert in kidney cancer, is Chair of the Department of Medicine and Physician-in-Chief at Vanderbilt University Medical Center.

“How we set up patients for success comes not just in our individual clinical encounters, but also how we approach patient care as an organization,” says Niels V. Johnsen, MD, MPH.

"The background for this paper stems from the increasingly identified need to do a better job of management of urinary tract infection, not only from a recognition standpoint, but also from a diagnostic and treatment standpoint," says Roger R. Dmochowski, MD, MMHC, FACS.

“I think the key to remember for a lot of what we're doing is that kidney stone disease is complicated. It's a really heterogenous patient population,” says Nicholas L. Kavoussi, MD.

"The ABU continues to reevaluate all policies related to diplomates. As medical practice continues to evolve in United States, and these changes affect the practitioners of medicine, likely further changes will be necessary in board certification procedures," writes Roger Dmochowski, MD, MA (Conflict Management and Resolution), MMHC, FACS.

A multidisciplinary team at the Vanderbilt Institute for Surgery and Engineering is collaborating on a 3D navigational system to help limit kidney stone fragments that remain after surgery.

The study assessed 120 women with overactive bladder for associations between anxiety and somatic symptoms, quality of life, quantitative sensory testing measures, and psychological stress symptoms.

Active surveillance is the preferred treatment option for men with low-risk prostate cancer and an option for some men with favorable intermediate-risk prostate cancer.

“This fellowship was one of the first FPRMS fellowships and one of only three ever created which fully incorporated both urology and gynecology in a single training program,” said Roger Dmochowski, MD.

“Vanderbilt researchers are participating in numerous projects related to PRS and disease risk; studies such as this highlight the importance of evaluating whether novel clinical tools actually enhance care,” said Kerry Schaffer, MD.

"Given that PCR testing may have a benefit for specific cohorts, it is recommended that more clinical evidence be provided to better guide Medicare in defining 'medical necessity,' ” write Stephanie Gleicher, MD, MPH, and Roger R. Dmochowski MD, MMHC, FACS.

Researchers compared survey responses from patients who had in-person visits and those who used telehealth consultations at Vanderbilt University Medical Center.

“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

“I would say that we did not anticipate the degree of potential cost savings,” says Ruchika Talwar, MD.

“Our study offers molecular and cellular insights into this aggressive subtype of prostate cancer, which we hope will ultimately impact patient care,” said the study’s lead author, Hong Yuen Wong, PhD.